KEAN LAB
  • Home
  • RESEARCH
    • Clinical Studies >
      • PREDICT
      • Abatacept
    • Translational Studies >
      • GVHD
      • Immune Tolerance
      • Cellular Therapies
  • Publications
  • People
    • Lab Team
    • Clinical Team
    • Collaborators
  • Funding
  • MEDIA
  • Global
  • Contact

Active grants

R33 AI116184 (Kean)                                                                                   
NIH/NIAID                                                                               
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation 
The goal of this project is to explore the mechanisms by which haplo-identical bone marrow transplantation can cure HIV infection using a non-human primate model.
Specific Aims: The specific aims of this project are (1) to create a Non-human Primate Model of Haploidentical HCT for HIV Eradication and (2) to determine whether haploidentical HCT using HIV-resistant stem cells expressing the mC46 resistance factor can eradicate the viral reservoir from SHIV-c infected RMs.
Role: Principal Investigator  
​

R33 AI116184 (Kean)                                                                                 
NIH/NIAID                                                                               
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques 
This project seeks to find new insights into the biology of organ-specific T cell pathophysiology, new therapeutic options for GVHD treatment, and new approaches to tolerogenic GVHD prevention.
Specific Aims: The specific aims of this project involve (1) evidence-based GVHD Prevention, (2) tissue-specific GVHD diagnostics, and (3) evidence-based GVHD treatment
Role: Principal Investigator  
​

U19 AI051731 (Larson)                                                         
Emory University/NIAID
Project 2:  Transplant Tolerance in Non-Human Primates 
The goal of this project is to use mixed-chimerism- and Treg-based approaches to induce specific immunologic tolerance during bone marrow and renal transplantation in a rhesus macaque MHC-defined transplant model.
Specific Aims: The specific aims of this project are (1) to engineer an optimally suppressive regulatory T cell product, able to provide allograft-specific immune tolerance after renal transplantation; (2)  to induce immune tolerance to a renal allograft through the induction of stable, multilineage mixed-hematopoietic chimerism and preservation of protective immunity in the setting of T cell costimulation blockade.
Role:  Principal Investigator 
​

Core B:  Transplant Tolerance in Non-Human Primates 
The goal of this core is to support all projects being performed as part of the Transplant Tolerance in Non-Human Primates U19 in the following areas:  (1) MHC immunogenetic analysis; (2) Determining the impact of transplantation on anti-viral protective immunity; (3) Transplant-specific histopathology; and (4) Multiparameter flow-cytometric immune analysis. 
Specific Aims: The specific aims of this project are (1) to engineer an optimally suppressive regulatory T cell product, able to provide allograft-specific immune tolerance after renal transplantation; (2)  to induce immune tolerance to a renal allograft through the induction of stable, multilineage mixed-hematopoietic chimerism and preservation of protective immunity in the setting of T cell costimulation blockade.
Role:  Principal Investigator 
​

U19 HL129902 (Cannon)                                
USC/FHCRC                                                              
Next Generation HSC Gene Therapy for HIV Control and Eradication  Project 1: 
Defining HIV Sanctuary Sites During Autologous and Allogeneic Transplantation The goal of this project is to investigate the ability of hematopoietic stem cell transplantation with HIV-resistant cells to eradicate the viral reservoirs that persist during cART and cure HIV, having the potential to contribute to the healthy lives of HIV-infected patients, by producing a definitive cure of their disease.
Specific Aims: The specific aims of this project are (1) to create an anatomic, cellular and temporal map of transplant-resistant sanctuary sites after auto-HCT with gene-modified, SHIVresistant hematopoietic stem cells (HSCs); (2) to determine the ability of allo-HCT, with and without SHIV-resistant cells, to clear the viral reservoir.
Role:  Principal Investigator 
​

FP01024468  (Kean/Stenger)                                 
Thrasher Research Fund/Emory                  
 Acute GVHD Suppression Using Co-Stimulation Blockade to Expand Non-Malignant Transplant – ASCENT 
Specific Aims: Dr. Leslie Kean will be responsible for overseeing the clinical trial laboratory correlatives being completed in her laboratory. This will include flow cytometry and viral assay of 26 patients x 10 timepoints.
Role:  Co-Principal Investigator 

Biopharma collaborations

The Kean lab has ongoing collaborations with the following biopharma companies: 
  • Bristol Myers Squibb 
  • Regeneron 
  • Magenta 
  • Bluebird Bio
HOME​          RESEARCH          PEOPLE           FUNDING          MEDIA          CONTACT           GLOBAL
Powered by Create your own unique website with customizable templates.
  • Home
  • RESEARCH
    • Clinical Studies >
      • PREDICT
      • Abatacept
    • Translational Studies >
      • GVHD
      • Immune Tolerance
      • Cellular Therapies
  • Publications
  • People
    • Lab Team
    • Clinical Team
    • Collaborators
  • Funding
  • MEDIA
  • Global
  • Contact